tafasitamab – Patient Worthy

[Source: pixabay.com]

First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL

Post author:Jessica Lynn
Post published:May 14, 2021
Post category:Diffuse Large B-cell Lymphoma

For many patients with diffuse large B-cell lymphoma (DLBCL), one first-line treatment is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, even aggressive chemotherapy is not always enough for patients…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More